Science news
A subgroup of patients with a devastating
brain tumor called glioblastoma multiforme benefited from treatment with
a class of chemotherapy drugs that two previous large clinical trials
indicated was ineffective against the disease, according to a study at
the Stanford University School of Medicine.
Specifically, patients in the subgroup who were treated with
chemotherapy drugs that block the growth of new blood vessels in the
tumor lived an average of about one year longer than those who were
given other classes of chemotherapy drugs, the researchers found.
The retrospective study emphasizes the importance of properly
categorizing tumors with varied biology in order to best personalize
treatment for each patient. Lumping all glioblastoma patients together
as one group led to the flawed conclusion that no patients benefited
from anti-angiogenesis treatments, the researchers said.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.